OMRON Corporation

IAB has built a "Customer Base Map" that visualizes 110,000 customers globally, expanding its customer base around a wide range of products including sensors and controllers. In FY2025, the company released 22 new product models, achieving year-on-year sales growth of 12.3% and operating profit growth of 18.0%. Its industry-leading product lineup forms a barrier to competitor entry.

HCB sells medical devices, centered on blood pressure monitors, in more than 130 countries worldwide, and its smartphone app "OMRON connect" has surpassed 15 million cumulative downloads across more than 130 countries and regions. The company has achieved technological differentiation, for example by globally rolling out next-generation blood pressure monitors equipped with the "Intellisense AFib" atrial fibrillation detection algorithm, which leverages over 50 years of accumulated pulse wave technology.

In October 2023, the company made JMDC a consolidated subsidiary, acquiring an anonymized medical data infrastructure sourced from health insurance associations and medical institutions. The DSB segment achieved high growth, with sales of ¥51,151 million in FY2026 (ending March 2026), up 19.7% year on year. By capturing demand for data utilization from pharmaceutical companies and insurers, and combining this data with Omron's device data, it serves as a differentiated foundation for preventive healthcare solutions.

Commenced the new medium-term roadmap "SF 2nd Stage" covering FY2026 through FY2030. Under the policy of "Trusted Growth - Further deepening customer trust toward transformation into a GEMBA DX company," the company is steadily executing growth plans for its 13 focus businesses. FY2027 (ending March 2027) financial targets on an IFRS basis are net sales of ¥820,000 million, operating profit of ¥62,000 million, ROE of approximately 5.5%, ROIC of approximately 4.0%, and EPS of ¥229.

Resolved by the Board of Directors on March 30, 2026, with the share transfer scheduled to be executed on October 1, 2026. DMB has been classified as Discontinued Operations, enabling management resources to be concentrated on the four core businesses: IAB, HCB, SSB, and DSB. Aims to improve profitability and capital efficiency through portfolio optimization.

Capital expenditure demand in the generative AI, semiconductor, and secondary battery fields is expected to remain strong throughout the year, and the company will continue the planned development and release of new products tailored to customer needs in each area. The FY2027 (ending March 2027) target for IAB external customer net sales is ¥440,000 million (+7.5% year on year), with an operating profit target of ¥44,000 million (+2.8% year on year).

Continuing to expand the number of "Pep Up" issued IDs by JMDC and increase data utilization transactions with pharmaceutical companies and insurance companies. FY2026 (ended March 2026) DSB external customer net sales achieved high growth of ¥51,151 million (+19.7% year on year). The FY2027 (ending March 2027) target is further expansion to ¥62,000 million (+21.2% year on year). The company aims to transform into a company that achieves new growth through data services from 2030 onward.

Voluntarily adopting IFRS from the first quarter of the consolidated fiscal year ending March 2027 (FY2027). This aims to improve comparability with global investors and enhance recognition in capital markets. Earnings forecasts and financial targets for FY2027 (ending March 2027) have already been disclosed on an IFRS basis. A challenge remains in explaining to investors the numerical fluctuations arising from differences in accounting policies compared to U.S. GAAP.